Zeming Liu1, Pan Yu1, Yiquan Xiong1, Wen Zeng2, Xiaoyu Li1, Yusufu Maiaiti1, Shuntao Wang1, Haiping Song1, Lan Shi1, Chunping Liu1, Bo Cheng1, Bo Zhang1, Jie Ming1, Fang Dong1, Hui Ge3, Xiu Nie3, Tao Huang1. 1. Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science And Technology Wuhan, People's Republic of China. 2. Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science And Technology Wuhan, Hubei, China. 3. Department of Pathology, Union Hospital, Tongji Medical College, Huazhong University of Science And Technology Wuhan, China.
Abstract
OBJECTIVES: To evaluate the expression and significance of CK19, TPO, and HBME-1 in the differential diagnosis of papillary thyroid carcinoma (PTC) and nonmalignant nodules. METHODS: Tissue samples were obtained from 257 patients with PTC and 149 patients with nonmalignant thyroid specimens, and immunohistochemical staining for CK-19, TPO, and HBME-1 was performed. RESULTS: The expression of CK-19, TPO, and HBME-1 was 96.3%, 12.0%, and 85.3%, respectively, for the PTC group. For nonmalignant thyroid lesions group, the expression of these markers was 40.4%, 86.2%, and 37.2%, respectively. Further, the expression of CK-19 and HBME-1 in PTCs was much higher than that in the benign thyroid lesions (P < 0.05). However, the positive expression of TPO in PTC specimens was much lower than that in the nonmalignant specimens (P < 0.05). CK-1 had the highest sensitivity (96.30%) for PTCs. The combination of the positive expression of CK-19 and negative expression of TPO had the highest sensitivity (98.50%), while that of the positive expression of HBME-1 and negative expression of TPO had the highest specificity (92.90%). CONCLUSIONS: The combination of positive expression of CK-19 or HBME-1 or negative expression of TPO can improve the specificity of the diagnosis of PTC.
OBJECTIVES: To evaluate the expression and significance of CK19, TPO, and HBME-1 in the differential diagnosis of papillary thyroid carcinoma (PTC) and nonmalignant nodules. METHODS: Tissue samples were obtained from 257 patients with PTC and 149 patients with nonmalignant thyroid specimens, and immunohistochemical staining for CK-19, TPO, and HBME-1 was performed. RESULTS: The expression of CK-19, TPO, and HBME-1 was 96.3%, 12.0%, and 85.3%, respectively, for the PTC group. For nonmalignant thyroid lesions group, the expression of these markers was 40.4%, 86.2%, and 37.2%, respectively. Further, the expression of CK-19 and HBME-1 in PTCs was much higher than that in the benign thyroid lesions (P < 0.05). However, the positive expression of TPO in PTC specimens was much lower than that in the nonmalignant specimens (P < 0.05). CK-1 had the highest sensitivity (96.30%) for PTCs. The combination of the positive expression of CK-19 and negative expression of TPO had the highest sensitivity (98.50%), while that of the positive expression of HBME-1 and negative expression of TPO had the highest specificity (92.90%). CONCLUSIONS: The combination of positive expression of CK-19 or HBME-1 or negative expression of TPO can improve the specificity of the diagnosis of PTC.
Entities:
Keywords:
Papillary thyroid carcinoma; cytokeratin-19; human bone marrow endothelial cell-1; thyroid peroxidase
Authors: C González-Lois; C Ballestín; M T Sotelo; F López-Ríos; M D García-Prats; V Villena Journal: Histopathology Date: 2001-06 Impact factor: 5.087
Authors: Georgios Geropoulos; Kyriakos Psarras; Maria Papaioannou; Dimitrios Giannis; Maria Meitanidou; Konstantinos Kapriniotis; Nikolaos Symeonidis; Efstathios T Pavlidis; Theodoros E Pavlidis; Konstantinos Sapalidis; Nada Mabrouk Ahmed; Tarek Ezzat Abdel-Aziz; Mohammad M R Eddama Journal: In Vivo Date: 2022 Jul-Aug Impact factor: 2.406